Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine Epigenetic Priming Followed by Rituximab-GDP in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
KCT0003502Phase 2Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, rituximab, gemcitabine, cisplatin, dexamethasone in diffuse large B-cell lymphoma (DLBCL), sponsored by Seoul National University Hospital. Started Mar 2019; status: recruiting.
02
Drugs
azacitidinerituximabgemcitabinecisplatindexamethasone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0003502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003502.